Only in Titles

           Search results for: Mycoplasma pneumoniae IgG ELISA kit   

paperclip

#24147043   2013/10/22 Save this To Up

High seroprevalence of Mycoplasma pneumoniae IgM in acute Q fever by enzyme-linked immunosorbent assay (ELISA).

Q fever is serologically cross-reactive with other intracellular microorganisms. However, studies of the serological status of Mycoplasma pneumoniae and Chlamydophila pneumoniae during Q fever are rare. We conducted a retrospective serological study of M. pneumoniae and C. pneumoniae by enzyme-linked immunosorbent assay (ELISA), a method widely used in clinical practice, in 102 cases of acute Q fever, 39 cases of scrub typhus, and 14 cases of murine typhus. The seropositive (57.8%, 7.7%, and 0%, p<0.001) and seroconversion rates (50.6%, 8.8%, and 0%, p<0.001) of M. pneumoniae IgM, but not M. pneumoniae IgG and C. pneumoniae IgG/IgM, in acute Q fever were significantly higher than in scrub typhus and murine typhus. Another ELISA kit also revealed a high seropositivity (49.5%) and seroconversion rate (33.3%) of M. pneumoniae IgM in acute Q fever. The temporal and age distributions of patients with positive M. pneumoniae IgM were not typical of M. pneumoniae pneumonia. Comparing acute Q fever patients who were positive for M. pneumoniae IgM (59 cases) with those who were negative (43 cases), the demographic characteristics and underlying diseases were not different. In addition, the clinical manifestations associated with atypical pneumonia, including headache (71.2% vs. 81.4%, p=0.255), sore throat (8.5% vs. 16.3%, p=0.351), cough (35.6% vs. 23.3%, p=0.199), and chest x-ray suggesting pneumonia (19.3% vs. 9.5%, p=0.258), were unchanged between the two groups. Clinicians should be aware of the high seroprevalence of M. pneumoniae IgM in acute Q fever, particularly with ELISA kits, which can lead to misdiagnosis, overestimations of the prevalence of M. pneumoniae pneumonia, and underestimations of the true prevalence of Q fever pneumonia.

1797 related Products with: High seroprevalence of Mycoplasma pneumoniae IgM in acute Q fever by enzyme-linked immunosorbent assay (ELISA).

Mycoplasma pneumoniae IgM Alkaline Phospatase (ALP) GLP 1 ELISA Kit, Rat Gluc Screen Quest™ Colorimet Screen Quest™ Colorimet Screen Quest™ Fluorimet Screen Quest™ Fluorimet Infection diseases: Heli Human high sensitivity in EnzyChrom™ Kinase Assay Leptin ELISA Kit, Human A MarkerGene™ Cellular Se

Related Pathways

paperclip

#20701743   2010/09/06 Save this To Up

Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

Mycoplasma pneumoniae is responsible for acute respiratory tract infections (RTIs) common in children and young adults. As M. pneumoniae is innately resistant to beta-lactams antibiotics usually given as the first-line treatment for RTIs, specific and early diagnosis is important in order to select the right treatment. Serology is the most used diagnostic method for M. pneumoniae infections.

2521 related Products with: Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

AtpB | beta subunit of AT AtpB | beta subunit of AT ATP synthase H+ transport pCMVLuxB Mammalian LuxB E Anti-ATPase, (Na(+) K(+)) Anti ATPase, (Na(+) K(+)) anti GSK3 Beta IgG2a (mon BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 succinate-CoA ligase, GDP ATPase beta3(Na+ K+) anti ATP synthase C mature ant

Related Pathways

paperclip

#12806926   2003/06/16 Save this To Up

[Evaluation of a rapid IgM antibody detection kit for diagnosis of Mycoplasma pneumoniae infection during childhood].

We evaluated the utility of a rapid detection kit for Mycoplasma pneumoniae (Mp)-specific IgM antibody, ImmunoCard (IC) Mycoplasma Test (Meridian Bioscience, USA), with regard to mycoplasmal infection during childhood. For this purpose, 30 serum samples were obtained from 23 pediatric patients with serologically proved mycoplasmal pneumonia at and younger than 16 years of age. The diagnosis of mycoplasmal infection was made by means of a particle agglutination (PA) method, which was on the basis of 1) a four fold or greater rise with paired sera or 2) at and more than 1:640 with a single, acute phase serum. In addition to the IC test, Mp-specific IgM and IgG antibodies were measured by ELISA tests (Zeus, USA) for comparison. A final observation time for colorization in the IC test was prolonged to 10 min in this study. The reason for this was because only 8 samples which were obtained 5 days or more after the onset of fever (37.5 degrees C) were judged to be positive when the observation time was confined to 5 min as the manufacturer recommended. A judgment was always made by more than one persons. Since we intended to find out the diagnostic capability of the IC test using an acute phase single serum, we focused on 18 cases for which samples were obtained within 5 days of the onset of fever. As a result, 13 (72%) cases were judged to be positive for Mp by the IgM ELISA test, 6 (33%) cases, including 5 cases in which the result was interpreted to be positive by a 10-min observation, were judged to be positive by the IC test, and 4 (22%) cases were judged to be positive by the PA test when titers of at and more than 1:320 by an acute phase single serum were interpreted as significant. Through this study we felt that the sensitivity of the IC test was not so high as have been previously reported in the literatures (the IC test was occasionally positive even in the range of < 1:40 by a PA test). On the other hand, we believe that the 10-min observation for final colorization did not significantly affect the specificity of the IC test as long as it was compared with the results by the ELISA IgM test. So far, the rapidity in obtaining results, and the simplicity of handling by which the test can be performed in an outpatient clinic, are thought to be the major advantages of the IC test.

1385 related Products with: [Evaluation of a rapid IgM antibody detection kit for diagnosis of Mycoplasma pneumoniae infection during childhood].

Beta Amyloid (40) ELISA K Beta Amyloid (1 42) ELISA Antibody array detection Rapid Mouse Ig Isotyping Rapid Mouse Ig Isotyping Rapid Mouse Ig Isotyping Human anti-parainfluenza Human heparin (Hep) antib Human borrelia burgdorfer MarkerGeneTM Fluorescent MOUSE ANTI HUMAN CD15, Pr Mycoplasma pneumoniae IgM

Related Pathways

paperclip

#12376023   2002/10/11 Save this To Up

Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.

A prospective study was conducted to identify and characterize hospitalizations for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with serologic evidence of infection with Mycoplasma pneumoniae (Mp). Two hundred forty hospitalizations for AECOPD were included in a 17-month prospective study. Paired sera were obtained for each of the hospitalizations and were tested serologically for Mp using a commercial enzyme immunoassay (EIA) kit. Only significant changes, according to the formula in the manufacturer's instructions, in antibody titers for IgM and/or IgG and/or IgA were considered diagnostic for Mp infection. In 34 hospitalizations (14.2%) the serologic tests for Mp were positive (MpH). In 29 of these hospitalizations (85%) a significant change in IgA was found. In 11 of these hospitalizations (32%) the only change identified was in IgA. In 24 MpH (71%) there was serologic evidence for infection with at least one other respiratory pathogen. In comparison to the 206 hospitalizations without serologic evidence of infection with Mp, MpH had higher rates of inhaled steroid therapy (41% vs. 24%, p = 0.033) and a longer time interval between the appearance of dyspnea and hospitalization (6.6 +/- 3.8 days vs. 5.0 +/- 3.5 days, p = 0.012). There were no significant differences between these two groups in a broad spectrum of patient- and exacerbation-related clinical variables. Specific antibiotic therapy for Mp in the MpH group did not shorten the hospital stay. Serologic evidence of Mp infection is common in patients hospitalized for AECOPD, and is usually based on changes in specific IgA antibody titers. In most MpH another respiratory pathogen can be identified. The vast majority of clinical characteristics are the same in patients with and without serologic evidence of infection with Mp. The practical implications of these findings should be clarified in further studies.

1106 related Products with: Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.

BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 Infection diseases: Heli Infection diseases: Heli Liver cancer tissue array Liver tissue cancer tissu Hepatocellular carcinoma Ofloxacin CAS Number [824 Mycoplasma pneumoniae IgA Mycoplasma pneumoniae IgG Mycoplasma pneumoniae IgM Mycoplasma pneumoniae Ant

Related Pathways

  •  
  • No related Items